Table 1 Key DNA methylation findings in schizophrenia studies
Gene/Region | Sample type | Key findings | References |
|---|---|---|---|
BDNF | Blood | BDNF Val66Met polymorphism is associated with positive symptoms, cognitive function, and antipsychotic treatment response in schizophrenia | Farcas et al. [48] |
MB-COMT, DRD2, NR3C1 | Blood | Methylation status of MB-COMT, DRD2, and NR3C1 differentiates schizophrenia from controls | Aytac et al. [52] |
TCF4 | Peripheral Blood | Altered methylation and expression profiles in drug-free patients | Yazarlou et al. [53] |
SHANK3 | PBMCs | Methylation levels correlated with negative symptoms and left inferotemporal cortex volume | Ni et al. [54] |
CYP2E1 | Blood | Lower methylation levels in promoter region of CYP2E1 gene associated with schizophrenia and tardive dyskinesia | Zhang et al. [59] |
Gad67, Reln, Bdnf | Brain tissue | Hypermethylation reduced by DNA methyltransferase 1 inhibitor RG108 | Wawrzczak-Bargiela et al. [60] |